DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases

Ruixin Ge, Miao Chen, Sijin Wu, Sirui Huang, Ping Zhou, Minghui Cao, Fan Zhang, Jinzhi Zang, Yigao Zhu, Jingrui Li, Guilin Ni, Zhihao Yang, Qingchao Li, Wei Pan, Liang Zhang, Min Liu, Chenghao Xuan, Haiyang Yu*, Jun Zhou*, Songbo Xie*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Oligonucleotide-based medicine faces challenges in efficiently crossing the blood-brain barrier and rapidly reducing toxic proteins. To address these challenges, here we establish an integrated modality, brain-penetrant DNA nanoflowers incorporated with oligonucleotide-based proteolysis targeting chimeras. Using FUS as a proof-of-concept, mutations of which cause frontotemporal dementia and amyotrophic lateral sclerosis, we demonstrate that a FUS-engaging RNA oligonucleotide crosslinked to a ligand for Cereblon efficiently degrade FUS and its cytoplasmic disease-causing mutants through a ubiquitin-proteasomal pathway. The DNA nanoflower contains hundreds of oligonucleotide binding sites and transferrin receptor-engaging aptamers, allowing efficient loading of the oligonucleotide-based degrader and engaging transferrin receptors for brain delivery. A single dose intravenous injection of this modality reaches brain parenchyma within 2 h and degrades 80% FUS protein there, sustained for two weeks without noticeable toxicity. DNA nanoflower oligonucleotide-based degrader is a therapeutic strategy for neurodegenerative diseases that leverages the advantages of designer oligonucleotides and targeted protein degradation.

Original languageEnglish
Article number4683
JournalNature Communications
Volume16
Issue number1
DOIs
Publication statusPublished - Dec 2025

Fingerprint

Dive into the research topics of 'DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases'. Together they form a unique fingerprint.

Cite this